Literature DB >> 6846164

Pharmacokinetic and pharmacodynamic effects of diltiazem.

M S Smith, C P Verghese, D G Shand, E L Pritchett.   

Abstract

The pharmacokinetic and pharmacodynamic effects of diltiazem were studied in 8 patients after a short intravenous infusion (20 mg over 10 minutes), a single oral dose (60 or 90 mg), and repeated oral administration (60 or 90 mg every 6 hours for 16 doses). Diltiazem levels decreased in a triexponential manner after intravenous infusion. Terminal half-lives after intravenous, single oral, and repeated oral administration were not significantly different (4.5 +/- 1.3, 3.7 +/- 0.6, and 4.9 +/- 0.4 hours, respectively). The kinetic effects of oral diltiazem were nonlinear. With repeated oral administration, there was accumulation of both diltiazem and its metabolite, deacetyldiltiazem. The diltiazem area under the time versus concentration curve increased by a factor of 2.39 +/- 0.42 (p = 0.00002). Most patients showed a double peaked time versus concentration curve after oral administration, indicating possible enterohepatic recirculation. After intravenous administration, there was a substantial increase in the P-R interval (14.3 +/- 5.4%). Although only small changes in P-R interval were seen with a single oral dose, with chronic administration there was persistent P-R interval prolongation, peaking at 17.3 +/- 5.6% over control. Counterclockwise hysteresis was present in the P-R interval versus plasma diltiazem concentration curve after intravenous administration. Only small changes were seen in heart rate and blood pressure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846164     DOI: 10.1016/0002-9149(83)90314-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Performance of diltiazem tablet and multiparticulate osmotic formulations in the dog.

Authors:  S C Sutton; K Engle; R A Deeken; K E Plute; R D Shaffer
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

Review 2.  Bioequivalence of controlled-release calcium antagonists.

Authors:  R Schall; F R Müller; F O Müller; H G Luus
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 3.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 4.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

5.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 6.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

7.  N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives.

Authors:  S C Montamat; D R Abernethy
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

8.  Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies.

Authors:  W Homsy; M Lefebvre; G Caillé; P du Souich
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 9.  The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials.

Authors:  C J Bulpitt; A E Fletcher; A Amery; J Coope; J G Evans; S Lightowlers; K O'Malley; A Palmer; J Potter; P Sever
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

10.  Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.

Authors:  G Caillé; S Boucher; J Spénard; Z Lakhani; A Russell; J Thiffault; M G Grace
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.